☆ 4.6 Review

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA)

Tatsuya Ioka et al.

Summary: This study demonstrates that adding S-1 to GC can improve overall survival and response rate in patients with advanced biliary tract cancer, making GCS a potential new first-line standard chemotherapy. Additionally, GCS is being tested in a neoadjuvant trial to further evaluate its efficacy.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2023)

Add to Collection

Meeting Abstract Oncology

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

Do-Youn Oh et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Platinum-Based Chemotherapy ?Rechallenge? in Advanced Non-ovarian Solid Malignancies

J. Hack et al.

Summary: Platinum rechallenge has been widely adopted in the treatment of certain cancers, but there is a lack of quality evidence to support its use in other malignancies. For patients with advanced disease, factors such as efficacy, treatment-related toxicity, and quality of life are critical considerations in treatment recommendations.

CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study

Mario Rizzato et al.

Summary: A study of 286 patients with biliary tract cancer revealed that FGFR2/3 aberrations and IDH1/2 mutations may serve as prognostic factors for survival in these patients. The recognition and assessment of their prognostic impact is important for the interpretation of existing data and the design of new therapeutic trials.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer

Felix Thol et al.

Summary: This study evaluated the outcomes of patients with advanced biliary tract cancer undergoing different oncological therapies, with FOLFIRINOX treatment associated with extended overall survival. Various clinical parameters like albumin, bilirubin, and tumor markers were found to be associated with survival.

JHEP REPORTS (2022)

Add to Collection

Article Oncology

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future

Alessandro Rizzo et al.

Summary: Recent years have witnessed breakthroughs in the treatment of advanced biliary tract cancer, including targeted therapies based on molecular understanding and the development of novel treatments. This review provides an overview of systemic treatment for metastatic BTC, summarizing recent clinical data on chemotherapy as well as the main results of targeted therapies and immunotherapy.

CURRENT ONCOLOGY (2022)

Add to Collection

Article Oncology

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study

Juan W Valle et al.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliarytract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study

Changhoon Yoo et al.

Summary: The addition of liposomal irinotecan to fluorouracil and leucovorin significantly improved progression-free survival in advanced biliary tract cancer patients who had progressed on gemcitabine plus cisplatin. Liposomal irinotecan plus fluorouracil and leucovorin could be considered as a standard-of-care second-line therapy for advanced biliary tract cancer, with manageable safety profile.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Angela Lamarca et al.

Summary: This study found that second-line FOLFOX chemotherapy can significantly improve overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, indicating it should be considered as standard-of-care chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors

Leigh Marcus et al.

Summary: The FDA approved pembrolizumab for the treatment of TMB-H solid tumors in adults and children, based on its significant overall response rate and duration in clinical trials. This marks the first FDA approval of a cancer treatment based on TMB, and the fourth based on a biomarker rather than primary site.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Pharmacology & Pharmacy

Infigratinib: First Approval

Connie Kang

Summary: Infigratinib, a FGFR-specific tyrosine kinase inhibitor, has been approved in the USA for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with specific genetic abnormalities.

DRUGS (2021)

Add to Collection

Article Oncology

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Milind Javle et al.

Summary: The study evaluated the activity of pertuzumab plus trastuzumab in patients with HER2-positive metastatic biliary tract cancer. The results showed a promising response rate and good tolerability, suggesting the need for further randomized, controlled trials in this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer

Hongsik Kim et al.

Summary: This study revealed that TMB-H in advanced BTCs did not have a prognostic role in the standard first-line treatment, but might be a predictive biomarker for response to ICIs.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)

Add to Collection

Article Pharmacology & Pharmacy

Pemigatinib: First Approval

Sheridan M. Hoy

DRUGS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer

Mairead Geraldine McNamara et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Third-line chemotherapy in advanced biliary cancers (ABC): Pattern of care, treatment outcome and prognostic factors from a multicenter study

A. Rizzo et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Vivek Subbiah et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Leigh Marcus et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Maeve A. Lowery et al.

CANCER (2019)

Add to Collection

Article Gastroenterology & Hepatology

Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study

Daryl Ramai et al.

MINERVA GASTROENTEROLOGICA E DIETOLOGICA (2019)

Add to Collection

Review Oncology

Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review

Audra N. Boscoe et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Apinya Jusakul et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Oncology

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J. W. Valle et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Oncology

Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise

Supriya K. Saha et al.

ONCOLOGIST (2016)

Add to Collection

Review Oncology

Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency

Vitor Werneck Krauss Silva et al.

CHINESE CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Gallbladder Cancer Incidence and Mortality, United States 1999-2011

S. Jane Henley et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2015)

Add to Collection

Article Oncology

Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study

Thomas Walter et al.

EUROPEAN JOURNAL OF CANCER (2013)

Add to Collection

Article Medicine, General & Internal

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.

Juan Valle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.